Abbott Laboratories $ABT Shares Sold by Keybank National Association OH

Keybank National Association OH lessened its position in shares of Abbott Laboratories (NYSE:ABT) by 1.3% during the 1st quarter, Holdings Channel reports. The institutional investor owned 1,289,584 shares of the healthcare product maker’s stock after selling 16,909 shares during the quarter. Keybank National Association OH’s holdings in Abbott Laboratories were worth $132,402,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of the stock. Freemont Management S.A. lifted its holdings in Abbott Laboratories by 197.2% during the 4th quarter. Freemont Management S.A. now owns 10,700 shares of the healthcare product maker’s stock worth $1,341,000 after buying an additional 7,100 shares during the last quarter. PFA Pension Forsikringsaktieselskab purchased a new position in shares of Abbott Laboratories in the 4th quarter valued at about $116,580,000. Danica Pension Livsforsikringsaktieselskab purchased a new stake in Abbott Laboratories during the third quarter worth approximately $185,640,000. Thrivent Financial for Lutherans raised its holdings in Abbott Laboratories by 24.3% during the fourth quarter. Thrivent Financial for Lutherans now owns 246,586 shares of the healthcare product maker’s stock worth $30,931,000 after purchasing an additional 48,286 shares in the last quarter. Finally, Net Worth Advisory Group acquired a new stake in Abbott Laboratories during the fourth quarter worth approximately $1,366,000. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Analyst Ratings Changes

A number of research analysts recently commented on the stock. Oppenheimer dropped their target price on shares of Abbott Laboratories from $132.00 to $115.00 and set an “outperform” rating on the stock in a research report on Friday, April 17th. Piper Sandler restated an “overweight” rating and issued a $115.00 price objective on shares of Abbott Laboratories in a research note on Monday, June 22nd. Barclays cut their target price on Abbott Laboratories from $144.00 to $143.00 and set an “overweight” rating on the stock in a research report on Monday, April 20th. Robert W. Baird started coverage on Abbott Laboratories in a report on Wednesday. They issued an “outperform” rating and a $121.00 target price for the company. Finally, Mizuho decreased their target price on Abbott Laboratories from $125.00 to $115.00 and set a “neutral” rating for the company in a research report on Friday, April 17th. Two investment analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $118.42.

Trending Headlines about Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Robert W. Baird initiated coverage on Abbott with an “outperform” rating and a $121 price target, signaling meaningful upside from current levels. Article Title
• Positive Sentiment: Baird’s bullish view follows a broader positive analyst backdrop, with another report highlighting Abbott among Wednesday’s notable Wall Street research calls. Article Title
• Positive Sentiment: Abbott also benefited from news that Tandem Diabetes Care launched compatibility for its t:slim X2 insulin pump with Abbott’s FreeStyle Libre 3 Plus sensor in five international markets, which may support adoption of Abbott’s diabetes device ecosystem. Article Title
• Positive Sentiment: Abbott cleared a major legal risk after the DOJ ended its criminal formula probe, removing a potential overhang that had weighed on the stock. Article Title
• Neutral Sentiment: Some recent coverage compares Abbott with Intuitive Surgical as a healthcare investment idea, but this is more commentary than a direct catalyst for the shares. Article Title

Abbott Laboratories Stock Up 3.3%

Shares of NYSE:ABT opened at $95.25 on Friday. Abbott Laboratories has a 1-year low of $81.97 and a 1-year high of $137.49. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.39 and a quick ratio of 1.01. The stock has a market cap of $165.91 billion, a P/E ratio of 26.68, a P/E/G ratio of 1.59 and a beta of 0.61. The firm has a fifty day moving average price of $88.88 and a 200 day moving average price of $104.41.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings data on Thursday, April 16th. The healthcare product maker reported $1.15 EPS for the quarter, beating analysts’ consensus estimates of $1.14 by $0.01. Abbott Laboratories had a net margin of 13.90% and a return on equity of 17.62%. The company had revenue of $11.16 billion for the quarter, compared to analyst estimates of $10.99 billion. During the same period in the previous year, the business posted $1.09 earnings per share. Abbott Laboratories’s quarterly revenue was up 7.8% on a year-over-year basis. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. Sell-side analysts predict that Abbott Laboratories will post 5.48 EPS for the current year.

Abbott Laboratories Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, August 17th. Shareholders of record on Wednesday, July 15th will be given a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a yield of 2.6%. The ex-dividend date of this dividend is Wednesday, July 15th. Abbott Laboratories’s dividend payout ratio (DPR) is presently 70.59%.

Insider Buying and Selling

In related news, CFO Philip P. Boudreau purchased 2,200 shares of the business’s stock in a transaction dated Thursday, April 23rd. The stock was acquired at an average price of $91.50 per share, for a total transaction of $201,300.00. Following the completion of the purchase, the chief financial officer directly owned 2,200 shares of the company’s stock, valued at $201,300. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Daniel J. Starks acquired 10,000 shares of the stock in a transaction that occurred on Monday, April 27th. The stock was purchased at an average price of $92.65 per share, for a total transaction of $926,500.00. Following the completion of the transaction, the director owned 6,751,103 shares in the company, valued at $625,489,692.95. The trade was a 0.15% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. 0.46% of the stock is currently owned by company insiders.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.